Equities analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will post sales of $59.43 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $76.70 million and the lowest estimate coming in at $14.30 million. Crispr Therapeutics reported sales of $120,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 49,425%. The company is expected to report its next earnings results on Monday, February 24th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current year, with estimates ranging from $226.90 million to $289.27 million. For the next fiscal year, analysts forecast that the company will post sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
Several research firms have recently issued reports on CRSP. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research report on Monday, December 16th. Oppenheimer boosted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. BidaskClub lowered Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 13th. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Finally, Chardan Capital reissued a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research report on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $71.38.
Shares of CRSP traded down $0.74 during trading hours on Thursday, hitting $66.01. The company had a trading volume of 999,939 shares, compared to its average volume of 985,513. The firm has a fifty day moving average price of $64.60 and a 200-day moving average price of $50.48. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of -19.19 and a beta of 3.31. Crispr Therapeutics has a 52-week low of $26.00 and a 52-week high of $74.00.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at $4,366,000. Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at $21,167,000. Granahan Investment Management Inc. MA grew its position in Crispr Therapeutics by 8.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock valued at $1,418,000 after acquiring an additional 2,655 shares during the last quarter. Barclays PLC grew its position in Crispr Therapeutics by 42.7% in the 3rd quarter. Barclays PLC now owns 13,877 shares of the company’s stock valued at $568,000 after acquiring an additional 4,151 shares during the last quarter. Finally, Stifel Financial Corp grew its position in Crispr Therapeutics by 18.0% in the 3rd quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock valued at $400,000 after acquiring an additional 1,491 shares during the last quarter. Institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.